Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
I have been in this for 3 years - traded some (but not enough) when it was in the teens - disappointed to see it drop on a lack of news. Pieces seem to be coming together and honestly think it would be crazy to sell at these levels - tightly held sharebase means the rise can be aggressive.
Good RNS - not many shares available - up 20% on 6.5k shares of volume.
Maybe I was harsh - but it has been a hard day! Chairman got better. I think investors would prefer more of a focus on numbers, exits, valuations - not generic backslapping on how well everything is going.
Listening to the presentation, CEO is coming across very well in my view. Exec chairman for me was like nails on a chalkboard - sounded like an auditor who had read a management speak for beginners book. A real struggle to sit through - keeps patting himself on the back for his practical turnaround and excellent progress. Reality check my friend - look at the share price. Happy to trust my investment with Ilian though..
I know markets are crappy at the moment but the sp reaction is very muted. The way I see it is ARCM is now completely derisked from a cash point of view, is in bed with a major and has a free exploration ride. Cash calls are the usual reason for AIM explorers to lose money for investors - and i see that risk as having materially been removed. From what others have said, the drilling will be speedy due to limited drilling windows, which implies the results will also come quickly. I have around a million of these, was happy topping up this morning at around 5.3 and am eagerly awaiting the call at 11 and the next 6 months. Should be looking for double digits minimum given the wait we have had for this deal. GLA
they have to say it is for general working capital. If not legally it can only be spent on the cuda deal - if that needs less cash or does not happen then they cant invest the cash elsewhere. I would not read too much into the working capital statement. the raise was for cuda.
Seems rather a lot - 40+ million shares for consulting, advisory & licensing. I know they are building a brand but that sounds like £600k+.
Hi all - holder here at tomco and pqe - does anyone know through which platform in Uk I can buy/trade us otc pqe ie pqeff either the actual shares or a derivative??
I think if the contract is going to a related party (ie major shareholder or director) then there needs to be a fairness opinion (run by other independent board members and checked by NOMAD) which would probably revolve around the competitive tender - to make sure the terms are reasonable. its sensible just to make sure there are no soft contracts to directors' companies with our money. Not true that all contacts need to be competitively tendered but obviously good practice to do so.
Anyone who has studied or practiced technical negotiations will know they usually go to the wire unless there is an incentive otherwise. Compromising before the end of the negotiating period is a sign of weakness. Look at Brexit - there was never going to be a results before any deadline - just talk. Same here in my opinion. Cant link the length of negotiation to the favourability or otherwise of the deal. My view is there will be an attractive deal or a short extension to one being signed.
This share remains one of the most infuriating and interesting in my portfolio - at the same time. When it was 50-55 it dropped to 45 despite clearly being undervalued. And now it is again making these counterintuitive moves. Given i dont want to trade it, the only way to keep my sanity is to remember we are 120%+ up on 2-3 weeks ago and now fully funded as is PDSB - so forgetting the 200p spike it has been a great month or so. As others have said, it is just a matter of time before we get some news and we move back up to 200p... Still a very good place to be in my opinion.
In your experience have you seen placees renegotiate when the price drops 10% or any %??? Laughable....
Glycotest has the potential to be very valuable and potentially much sooner than we think. Given Shanghai Fosun is the other shareholder with 30-40% and they are $20+ billion market cap asian pharma business. I cant see them wanting to bring in other investors through IPO or other fundraising. They will want control of Glycotest. I would also have thought NSCI may not want to become a minority holder which would cause a loss of control of their destiny. To me this points at either an increase in stake up to 49% for Fosun when Glycotest requires its next funding round (enough funds depending on valuation?) ... or.... a full buyout. Fosun would want to do this as soon as possible before the value is fully realised. Whatever happens the value is likely to be far higher than £11 million which is the fair value according to the BOD NAV. That's one of the reasons why despite missing out on Tuesday's spike I am happy to keep all my shares and let this play out.
If you hold 100,000 shares now. You subscribe to another 100,000 shares at 130p. Sell the ones now at a premium and its free profit.
.... have been on the sell all day. It looks to me that they have a seller. Volumes much lower than yesterday. Once JBER are cleared, I would suggest we are likely to move up back towards the 200 mark. Again PDSB stake is back up to £11.3 million which leaves £10.7 million for all 16 other stakes and cash. It was crazy undervalued at 45-55 3-6 months ago and with the announcement on Monday regarding AZ it remains crazy undervalued with a whole lot more potential. This past 24 hours has helped clear some of the day traders and hopefully added some IIs of LT PIs who will stick around for the ride.
Sounds like the Board is pretty confident the FEED study and the third party verification work will be a success. This is as good a lead indicator for a positive RNS as I have seen.
@Brady - you have missed the point - in the UK where 99% of the liquidity is, it does not make a difference to the ability to fund raise whether there are 2 billion or 200 million shares. I agree 2 billion is a bit low rent - but it really makes no difference - just look at COPLs ability to raise money in the past 6 months at a fraction of a penny, look at the large institutions taking a position. It does make a difference in N America hence the need to consolidate to open up that investment market. While i am happy for the company to just consolidate Atomic transaction, if there are new deals which are earnings accretive for shares or cash, then i am in favour as it will add to the value of my shareholding. think of a scenario where we want to take out the remaining ownership of the Atomic controlled fields but the owners are N America based and need a share with a higher share price as that is what their articles require - then it makes sense to consolidate. We have operating assets now so we should not need placings to cover exploration or admin costs which i would not be in favour of.
In terms of my agenda, I have a decent sized holding, which i would have thought allows me to "chime" in just as much as someone with 1 million shares or less. My agenda is the same as most here - see the value of my holding rise over the next 12 months.
In defence of the delays, in my day job we have acquired a number of private companies for which we needed to convert accounts to IFRS - it is a nightmare - they may be guilty of underestimating the work, but this is the advisers who wrongly advised there was no RTO required and therefore did not advise that the historic restatement would be required. Main thing is no skeletons in the closet. Also dont think for a moment that the CEO has anything to do with the restatement of the numbers - it is not his fault - the work is farmed out and he will have been waiting for the results just as impatiently as us. I dont want to sound like an Art apologist but there is a whole Board responsible here and I dont like the way some posters make personal attacks on individual members of the management team - would you like to be on the receiving end of such vitriol? GLA.